Ep. 56: Biologic Therapies for Asthma
Part of the series: Allergy, Asthma & Immunology Innovations Podcast
This podcast was made in partnership with Allergy & Asthma Network, with funding support from AstraZeneca.
This episode explores a new form of asthma treatment, Biologics. These innovative treatments offer targeted relief by addressing the underlying causes of asthma, leading to improved symptom control and a better quality of life. Dr. G and Kortney discuss the current biologics on the market for asthma treatment.
As this is a true deep dive, we have provided some more information about the Biologics discussed to help you build a better understanding. We have included images and graphs you can use when listening to the episode.
What we cover in biologic therapies for asthma episode:
A background on how Biologic treatments work.
The Biologics available for asthma - discuss who is a candidate, how they each work, how they are taken and some side effects.
Omalizumab (Xolair)
Mepolizumab
Reslizumab
Benralizumab
Dupilumab
Tezepelumab
What you need to know about biologic treatments for asthma
What are biologic therapies for asthma?
Biologic therapies are a type of medication that is made from living organisms. They work by targeting specific proteins that are involved in the immune system. Biologic therapies work by targeting specific proteins that are involved in the immune system.
Omalizumab targets immunoglobulin E (IgE), a key player in allergic reactions. By preventing IgE from binding to mast cells and basophils, Omalizumab reduces the release of inflammatory mediators, effectively minimizing asthma symptoms.
Mepolizumab, Reslizumab, and Benralizumab target eosinophils, cells associated with type 2 inflammation in asthma. By reducing the number and activity of eosinophils, these biologics help control asthma symptoms and improve overall lung function.
Dupilumab targets two cytokines, IL-4 and IL-13, which are crucial in type 2 inflammation. By blocking IL-4 and IL-13, Dupilumab helps reduce inflammation and asthma symptoms, relieving patients with moderate to severe asthma.
Tezepelumab targets thymic stromal lymphopoietin (TSLP), a key molecule involved in type 2 inflammation and the recruitment of inflammatory cells in the airways. By inhibiting TSLP, Tezepelumab effectively reduces inflammation and significantly improves symptoms for individuals with severe asthma.
DISCLAIMER -This graph is for educational purposes only and reflects what was discussed in the podcast, as Biologics are a newer treatment method, there may be changes that have been made after the airing of the podcast: Please ask your doctor for specific information. If you see any areas that should be updated, please contact us at theitchpodcast@gmail.com. Graph updated on 21/6/2023.
Image to help you understand the mechanisms of action in biological therapies
How effective are biologic therapies?
Biologic therapies can be very effective in treating asthma. In clinical trials, Biologic therapies have been shown to reduce asthma symptoms, improve lung function, and reduce the risk of asthma attacks.
Biologic therapies have brought a new era of hope for individuals living with asthma, offering targeted relief and improved symptom control. By specifically targeting key pathways and immune system components involved in asthma-related inflammation, these innovative treatments have the potential to transform the lives of asthma patients. As ongoing research and advancements continue in this field, Biologic therapies promise a brighter future, where individuals with asthma can experience better management and enhanced well-being.
Helpful links:
Helpful site that explains biologics in more depth: biologicmeds.org
More about type 2 inflammation: https://allergyasthmanetwork.org/news/when-asthma-more-than-asthma-type-inflammation/
